Site-active steroid provides symptomatic relief for patients with dry eye disease

Miami—Anti-inflammatory treatment using loteprednol etabonate suspension 0.2% (Alrex, Bausch & Lomb) appears to offer a safe and useful option for symptomatic relief in patients with dry eye, according to Roberto Beraja, MD.

Related Videos

Related Content

Advertisement

March 24th 2025

Opthea phase 3 clinical trial, COAST, in patients with wet age-related macular degeneration fails to meet primary endpoint

December 13th 2024

California dreaming: 2025 Glaucoma 360 brings celebration, innovation, and education to San Francisco

March 24th 2025

Unity Biotechnology releases topline results from phase 2b ASPIRE trial of UBX1325 in patients with diabetic macular edema

November 19th 2024

Connect, learn, and innovate in a family-friendly atmosphere: What to expect at EnVision Summit 2025

March 24th 2025

Importance of evaluating cerebrospinal fluid at vitreoretinal lymphoma diagnosis

March 24th 2025

Bausch + Lomb publishes results from phase 4 study evaluating patient-reported outcomes with Miebo in dry eye disease

Related Content

Advertisement

March 24th 2025

Opthea phase 3 clinical trial, COAST, in patients with wet age-related macular degeneration fails to meet primary endpoint

December 13th 2024

California dreaming: 2025 Glaucoma 360 brings celebration, innovation, and education to San Francisco

March 24th 2025

Unity Biotechnology releases topline results from phase 2b ASPIRE trial of UBX1325 in patients with diabetic macular edema

November 19th 2024

Connect, learn, and innovate in a family-friendly atmosphere: What to expect at EnVision Summit 2025

March 24th 2025

Importance of evaluating cerebrospinal fluid at vitreoretinal lymphoma diagnosis

March 24th 2025

Bausch + Lomb publishes results from phase 4 study evaluating patient-reported outcomes with Miebo in dry eye disease